Stock HLS HLS THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. HLS Therapeutics Inc.

Equities

HLS

CA40390B1094

Market Closed - Toronto S.E.
Other stock markets
 19:06:21 03/05/2024 BST 		5-day change 1st Jan Change
4.75 CAD +2.15% Intraday chart for HLS Therapeutics Inc. +2.15% +20.25%
04-08 HLS Therapeutics Inc. Announces Reduce-IT Analysis Results Relating the Effects of VASCEPA CI
03-14 Transcript : HLS Therapeutics Inc., Q4 2023 Earnings Call, Mar 14, 2024

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
HLS Therapeutics Downgraded to Hold at Stifel GMP on Revenue Concerns; Price Target Cut to C$5.00
MT
HLS Therapeutics Buy Rating Maintained at Stifel GMP as Growth Expectations Eased; Price Target Cut to C$12.25
MT
HLS Therapeutics Brief: Announcing Updates to its Credit Agreement; Term Extended, Borrowing capacity increases, Financial flexibility improves, and Interest rates remain relatively unchanged
MT
HLS Therapeutics Buy Rating Reiterated at Stifel GMP as Vascepa Prescriptions Rise; Price Target Kept at C$26.00
MT
HLS Therapeutics Reiterated at Buy at Stifel GMP on Rising Sales; Price Target Kept at C$32.00
MT
HLS Therapeutics Keeps Buy Rating at Stifel GMP Following Q2 Results; Price Target Cut to C$32.00
MT
HLS Therapeutics Buy Rating Maintained by Stifel GMP as Vascepa Sales Expand
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HLS Stock
  4. News HLS Therapeutics Inc.
  5. Analyst Reco.